Personalized and Precision Medicine Journal

Abstract Cancer remains one of humanity's leading causes of both illness and death globally. In women worldwide, breast cancer remains the most widespread malignant condition. The new possibilities for direct treatment offered by the advances made thereby were the subject of the recent study undertaken as it sought to unravel tumorigenesis through genetics and molecular appreciation of cancer. Specifically, this research centers on devising and testing immunotoxins as anti-bacterial toxin-based constructs to treat breast cancer. These immunotoxins can kill cancer cells selectively while leaving normal tissues unharmed as they bind only to cancer cell antigens by using both the specificity of antibodies and bacterial toxins' cytotoxicity power. We assessed immunotoxins' binding affinities to their respective antigens based on computational dockings like HADDOCK explaining encouraging results characterized by good docking scores accompanied by low RMSDs—also, dual targeting approaches combined with structure-based. By developing humanized antibodies and novel targeting moieties, challenges such as immunogenicity and non-specific toxicity have been tackled. Our findings suggest that optimized immunotoxins
have great potential to enhance therapeutic window as well as efficacy in cancer treatments

Abstract Immunotoxins have been used for cancer treatment. The immunotoxin binds to the surface antigen on the cancer cell, enters inside the cell by endocytosis1, and destroys the cancer cell. In addition, the components of this type of drug and assembly based on peptide bonds2, and the creation of recombinant protein construction were among the requirements investigated in this study. In this bioinformatics research, membrane antigen structural, and functional properties on the surface of breast cancer cells were investigated and evaluated to target cancer cells. An EGFR3 antigen with a shorter amino acid length for positive binding and INS4, which has 110 amino acids, binding +, and a binding score of 0.99, was selected as the most efficient ligand using the AAASGG 3 (GGGGS) linker5, resulting in a six-recombinant structure. Hence, the targeted treatment of cancer through immunotoxin with the confirmation of the patent sequence led to the creation of a recombinant structure, which was analyzed with bioinformatics software. To ensure accurate results in the laboratory, we utilized Escherichia coli strain DH5 as a host during the cloning phase for plasmid DNA replication. This enabled a more precise and reliable replication process, thereby confirming the validity of our computational modeling, and the results of this research led to the modeling and simulation of the engineering structure of Cetuximab ZZpe38 immunotoxin. For future research, gene expression in mammalian cells will be the focus.